Literature DB >> 33501884

Noninvasive stratification of nonalcoholic fatty liver disease by whole transcriptome cell-free mRNA characterization.

Naga Chalasani1, Shusuke Toden2, John J Sninsky2, Richard P Rava2, Jerome V Braun2, Samer Gawrieh1, Jiali Zhuang2, Michael Nerenberg2, Stephen R Quake3, Tara Maddala2.   

Abstract

Hepatic fibrosis stage is the most important determinant of outcomes in patients with nonalcoholic fatty liver disease (NAFLD). There is an urgent need for noninvasive tests that can accurately stage fibrosis and determine efficacy of interventions. Here, we describe a novel cell-free (cf)-mRNA sequencing approach that can accurately and reproducibly profile low levels of circulating mRNAs and evaluate the feasibility of developing a cf-mRNA-based NAFLD fibrosis classifier. Using separate discovery and validation cohorts with biopsy-confirmed NAFLD (n = 176 and 59, respectively) and healthy subjects (n = 23), we performed serum cf-mRNA RNA-Seq profiling. Differential expression analysis identified 2,498 dysregulated genes between patients with NAFLD and healthy subjects and 134 fibrosis-associated genes in patients with NAFLD. Comparison between cf-mRNA and liver tissue transcripts revealed significant overlap of fibrosis-associated genes and pathways indicating that the circulating cf-mRNA transcriptome reflects molecular changes in the livers of patients with NAFLD. In particular, metabolic and immune pathways reflective of known underlying steatosis and inflammation were highly dysregulated in the cf-mRNA profile of patients with advanced fibrosis. Finally, we used an elastic net ordinal logistic model to develop a classifier that predicts clinically significant fibrosis (F2-F4). In an independent cohort, the cf-mRNA classifier was able to identify 50% of patients with at least 90% probability of clinically significant fibrosis. We demonstrate a novel and robust cf-mRNA-based RNA-Seq platform for noninvasive identification of diverse hepatic molecular disruptions and for fibrosis staging with promising potential for clinical trials and clinical practice.NEW & NOTEWORTHY This work is the first study, to our knowledge, to utilize circulating cell-free mRNA sequencing to develop an NAFLD diagnostic classifier.

Entities:  

Keywords:  NASH; cell-free mRNA; classification biomarker; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis

Mesh:

Substances:

Year:  2021        PMID: 33501884      PMCID: PMC8238173          DOI: 10.1152/ajpgi.00397.2020

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  59 in total

Review 1.  Liver biopsy.

Authors:  A A Bravo; S G Sheth; S Chopra
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245

2.  Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Mohammad S Siddiqui; Raj Vuppalanchi; Mark L Van Natta; Erin Hallinan; Kris V Kowdley; Manal Abdelmalek; Brent A Neuschwander-Tetri; Rohit Loomba; Srinivasan Dasarathy; Danielle Brandman; Edward Doo; James A Tonascia; David E Kleiner; Naga Chalasani; Arun J Sanyal
Journal:  Clin Gastroenterol Hepatol       Date:  2018-04-26       Impact factor: 11.382

3.  Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Authors:  Brent A Neuschwander-Tetri; Rohit Loomba; Arun J Sanyal; Joel E Lavine; Mark L Van Natta; Manal F Abdelmalek; Naga Chalasani; Srinivasan Dasarathy; Anna Mae Diehl; Bilal Hameed; Kris V Kowdley; Arthur McCullough; Norah Terrault; Jeanne M Clark; James Tonascia; Elizabeth M Brunt; David E Kleiner; Edward Doo
Journal:  Lancet       Date:  2014-11-07       Impact factor: 79.321

4.  Circulating transcripts in maternal blood reflect a molecular signature of early-onset preeclampsia.

Authors:  Sarah Munchel; Suzanne Rohrback; Carlo Randise-Hinchliff; Sarah Kinnings; Shweta Deshmukh; Nagesh Alla; Catherine Tan; Amirali Kia; Grainger Greene; Linda Leety; Matthew Rhoa; Scott Yeats; Matthew Saul; Julia Chou; Kimberley Bianco; Kevin O'Shea; Emmanuel Bujold; Errol Norwitz; Ronald Wapner; George Saade; Fiona Kaper
Journal:  Sci Transl Med       Date:  2020-07-01       Impact factor: 17.956

Review 5.  Pathogenesis and novel treatment options for non-alcoholic steatohepatitis.

Authors:  Vincent Wai-Sun Wong; Shiv Chitturi; Grace Lai-Hung Wong; Jun Yu; Henry Lik-Yuen Chan; Geoffrey C Farrell
Journal:  Lancet Gastroenterol Hepatol       Date:  2016-08-10

6.  Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis.

Authors:  Yung Lee; Aristithes G Doumouras; James Yu; Karanbir Brar; Laura Banfield; Scott Gmora; Mehran Anvari; Dennis Hong
Journal:  Clin Gastroenterol Hepatol       Date:  2018-10-13       Impact factor: 11.382

7.  Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.

Authors:  Rohit Loomba; Victor Seguritan; Weizhong Li; Tao Long; Niels Klitgord; Archana Bhatt; Parambir Singh Dulai; Cyrielle Caussy; Richele Bettencourt; Sarah K Highlander; Marcus B Jones; Claude B Sirlin; Bernd Schnabl; Lauren Brinkac; Nicholas Schork; Chi-Hua Chen; David A Brenner; William Biggs; Shibu Yooseph; J Craig Venter; Karen E Nelson
Journal:  Cell Metab       Date:  2017-05-02       Impact factor: 27.287

8.  A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.

Authors:  Stephen A Harrison; Vlad Ratziu; Jérôme Boursier; Sven Francque; Pierre Bedossa; Zouher Majd; Geneviève Cordonnier; Fouad Ben Sudrik; Raphael Darteil; Roman Liebe; Jérémy Magnanensi; Yacine Hajji; John Brozek; Alice Roudot; Bart Staels; Dean W Hum; Sophie Jeannin Megnien; Suneil Hosmane; Noémie Dam; Pierre Chaumat; Rémy Hanf; Quentin M Anstee; Arun J Sanyal
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-08-05

9.  The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.

Authors:  Zobair M Younossi; Deirdre Blissett; Robert Blissett; Linda Henry; Maria Stepanova; Youssef Younossi; Andrei Racila; Sharon Hunt; Rachel Beckerman
Journal:  Hepatology       Date:  2016-09-26       Impact factor: 17.425

10.  Noninvasive diagnosis of fetal aneuploidy by shotgun sequencing DNA from maternal blood.

Authors:  H Christina Fan; Yair J Blumenfeld; Usha Chitkara; Louanne Hudgins; Stephen R Quake
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-06       Impact factor: 11.205

View more
  2 in total

1.  Cell types of origin of the cell-free transcriptome.

Authors:  Sevahn K Vorperian; Mira N Moufarrej; Stephen R Quake
Journal:  Nat Biotechnol       Date:  2022-02-07       Impact factor: 68.164

Review 2.  What Does the Future Hold for Patients With Nonalcoholic Steatohepatitis: Diagnostic Strategies and Treatment Options in 2021 and Beyond?

Authors:  Naim Alkhouri; Monica Tincopa; Rohit Loomba; Stephen A Harrison
Journal:  Hepatol Commun       Date:  2021-09-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.